Jagsonpal [JAGSNPHARM] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison

Jagsonpal

NSE
Loading...

Divi's Laboratories

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Jagsonpal wins in 12 metrics, Divi's Laboratories wins in 8 metrics, with 0 ties. Jagsonpal appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricJagsonpalDivi's LaboratoriesBetter
P/E Ratio (TTM)24.5965.37Jagsonpal
Price-to-Book Ratio6.2210.13Jagsonpal
Debt-to-Equity Ratio3.850.03Divi's Laboratories
PEG Ratio0.232.47Jagsonpal
EV/EBITDA24.8048.31Jagsonpal
Profit Margin (TTM)21.50%23.89%Divi's Laboratories
Operating Margin (TTM)15.69%25.60%Divi's Laboratories
EBITDA Margin (TTM)15.69%25.60%Divi's Laboratories
Return on Equity23.07%14.64%Jagsonpal
Return on Assets (TTM)19.90%12.94%Jagsonpal
Free Cash Flow (TTM)$549.52M$2.15BDivi's Laboratories
Dividend Yield1.01%0.91%Jagsonpal
1-Year Return26.76%8.12%Jagsonpal
Price-to-Sales Ratio (TTM)5.2415.71Jagsonpal
Enterprise Value$13.81B$1,480.60BDivi's Laboratories
EV/Revenue Ratio4.8815.34Jagsonpal
Gross Profit Margin (TTM)64.39%60.33%Jagsonpal
Revenue per Share (TTM)$42$363Divi's Laboratories
Earnings per Share (Diluted)$9.03$87.36Divi's Laboratories
Beta (Stock Volatility)0.150.18Jagsonpal
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Jagsonpal vs Divi's Laboratories Stock Performance Analysis

Loading Price Chart...

Jagsonpal
Divi's Laboratories
Jagsonpal Stock Overview | Divi's Laboratories Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Jagsonpal-0.47%2.97%-10.86%-3.68%-5.22%-14.79%
Divi's Laboratories2.73%3.10%-4.83%-14.69%1.79%-3.41%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Jagsonpal26.76%48.31%1,160.48%1,607.87%2,074.26%1,238.21%
Divi's Laboratories8.12%57.02%83.89%435.51%1,516.65%7,132.15%

News Based Sentiment: Jagsonpal vs Divi's Laboratories

Jagsonpal

News based Sentiment: MIXED

Jagsonpal Pharmaceuticals reported impressive financial results for FY25, exceeding previous performance metrics. However, a significant stock price decline and strong sell recommendations from analysts create a mixed investment picture, making September a pivotal month with conflicting signals for investors.

View Jagsonpal News Sentiment Analysis

Divi's Laboratories

News based Sentiment: MIXED

September presented a mixed bag for Divi's Laboratories, with stellar FY25 results overshadowed by a weaker Q1 FY26 performance and fluctuating analyst opinions. The Nifty 50 exclusion adds another layer of complexity, creating a dynamic investment scenario that requires careful monitoring.

View Divi's Laboratories News Sentiment Analysis

Performance & Financial Health Analysis: Jagsonpal vs Divi's Laboratories

MetricJAGSNPHARMDIVISLAB
Market Information
Market Cap i₹15.06B₹1.61T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i126,970437,716
90 Day Avg. Volume i125,054381,180
Last Close₹221.34₹5,866.00
52 Week Range₹158.62 - ₹328.04₹4,955.00 - ₹7,071.50
% from 52W High-32.53%-17.05%
All-Time High₹328.04 (Nov 25, 2024)₹7,071.50 (Jul 08, 2025)
% from All-Time High-32.53%-17.05%
Growth Metrics
Quarterly Revenue Growth0.23%0.14%
Quarterly Earnings Growth1.03%0.27%
Financial Health
Profit Margin (TTM) i0.22%0.24%
Operating Margin (TTM) i0.16%0.26%
Return on Equity (TTM) i0.23%0.15%
Debt to Equity (MRQ) i3.850.03
Cash & Liquidity
Book Value per Share (MRQ)₹35.72₹563.87
Cash per Share (MRQ)₹19.08₹132.86
Operating Cash Flow (TTM) i₹532.93M₹19.67B
Levered Free Cash Flow (TTM) i₹553.61M₹21.91B
Dividends
Last 12-Month Dividend Yield i1.01%0.91%
Last 12-Month Dividend i₹2.50₹60.00

Valuation & Enterprise Metrics Analysis: Jagsonpal vs Divi's Laboratories

MetricJAGSNPHARMDIVISLAB
Price Ratios
P/E Ratio (TTM) i24.5965.37
Forward P/E iN/A101.43
PEG Ratio i0.232.47
Price to Sales (TTM) i5.2415.71
Price to Book (MRQ) i6.2210.13
Market Capitalization
Market Capitalization i₹15.06B₹1.61T
Enterprise Value i₹13.81B₹1.48T
Enterprise Value Metrics
Enterprise to Revenue i4.8815.34
Enterprise to EBITDA i24.8048.31
Risk & Other Metrics
Beta i0.150.18
Book Value per Share (MRQ) i₹35.72₹563.87

Financial Statements Comparison: Jagsonpal vs Divi's Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)JAGSNPHARMDIVISLAB
Revenue/Sales i₹756.12M₹24.10B
Cost of Goods Sold i₹269.27M₹9.56B
Gross Profit i₹486.85M₹14.54B
Research & Development iN/AN/A
Operating Income (EBIT) i₹118.60M₹6.17B
EBITDA i₹170.38M₹8.48B
Pre-Tax Income i₹144.31M₹7.33B
Income Tax i₹36.36M₹1.88B
Net Income (Profit) i₹107.95M₹5.45B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)JAGSNPHARMDIVISLAB
Cash & Equivalents i₹112.15M₹4.15B
Total Current Assets i₹1.61B₹100.81B
Total Current Liabilities i₹259.04M₹14.52B
Long-Term Debt i₹76.32M₹20.00M
Total Shareholders Equity i₹2.40B₹149.69B
Retained Earnings i₹1.49B₹134.00B
Property, Plant & Equipment i₹82.26M₹3.19B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)JAGSNPHARMDIVISLAB
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricJAGSNPHARMDIVISLAB
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i126,970437,716
Average Daily Volume (90 Day) i125,054381,180
Shares Outstanding i66.40M265.47M
Float Shares i16.17M120.77M
% Held by Insiders i0.76%0.52%
% Held by Institutions i0.03%0.29%

Dividend Analysis & Yield Comparison: Jagsonpal vs Divi's Laboratories

MetricJAGSNPHARMDIVISLAB
Last 12-Month Dividend i₹2.50₹60.00
Last 12-Month Dividend Yield i1.01%0.91%
3-Year Avg Annual Dividend i₹1.37₹50.00
3-Year Avg Dividend Yield i0.66%0.70%
3-Year Total Dividends i₹4.10₹150.00
Ex-Dividend DateSep 12, 2025Jul 25, 2025